All In MedTech

FDA Clearance Tracker · P150026-S015

HeartLight Catheter, HeartLight X3 Console V2

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 11, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Aug 11, 2023

Approved

Time to decision

162 days

Received Mar 2, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P150026-S015
Device name
HeartLight Catheter, HeartLight X3 Console V2
Applicant location
Marlborough, MA
Received
Mar 2, 2023
Decided
Aug 11, 2023
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Location Change - Manufacturer/Sterilizer/Packager/Supplier
Original approval
P150026

Device type

Device class
Class III

Every decision under product code OAE

FDA's approval statement

As written in FDA's record.

Approval for the transition of the Console manufacturing from the current contractor, Minnetronix, 1635 Energy Park Dr, St Paul, MN 55108 USA to Gener8, 2560 Junction Ave., San Jose CA 95134 USA.

Source documents

Other decisions for Cardiofocus, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

1 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.